➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: July 25, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,230,098

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,230,098 protect, and when does it expire?

Patent 7,230,098 protects XALKORI and is included in one NDA.

This patent has forty-six patent family members in thirty-two countries.

Summary for Patent: 7,230,098
Title:Aminoheteroaryl compounds as protein kinase inhibitors
Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET ##STR00001##
Inventor(s): Cui; Jingrong Jean (San Diego, CA), Bhumralkar; Dilip (San Diego, CA), Botrous; Iriny (San Diego, CA), Chu; Ji Yu (Fremont, CA), Funk; Lee A. (Oceanside, CA), Hanau; Cathleen Elizabeth (Chesterfield, MO), Harris; G. Davis (Chesterfield, MO), Jia; Lei (San Diego, CA), Johnson; Joanne (Guilderland, NY), Kolodziej; Stephen A. (Ballwin, MO), Kung; Pei-Pei (San Diego, CA), Li; Xiaoyuan (Sharon) (Los Altas, CA), Lin; Jason (Qishen) (San Diego, CA), Meng; Jerry Jialun (San Diego, CA), Nambu; Mitchell David (San Diego, CA), Nelson; Christopher G. (Fresno, CA), Pairish; Mason Alan (San Diego, CA), Shen; Hong (San Diego, CA), Tran-Dube; Michelle (La Jolla, CA), Walter; Allison (Rexford, NY), Zhang; Fang-Jie (Sunnyvale, CA), Zhang; Jennifer (Foster City, CA)
Assignee: Sugen, Inc. (South San Francisco, CA)
Application Number:10/786,610
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 7,230,098

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-001 Aug 26, 2011 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-002 Aug 26, 2011 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,230,098

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2114 ⤷  Try it Free
Australia 2004215428 ⤷  Try it Free
Brazil PI0407827 ⤷  Try it Free
Canada 2517256 ⤷  Try it Free
China 103265477 ⤷  Try it Free
China 1777427 ⤷  Try it Free
Costa Rica 7961 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.